Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 4: Short-term Objective B  

$20,162,709.18
Fiscal Year: 2009

Green dot: Objective has greater than or equal to the recommended funding.4SB. Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012. IACC Recommended Budget: $75,000,000 over 5 years.

Download 2009 Question 4: Short-term Objective B projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
Role of a novel Wnt pathway in autism spectrum disorders Reichardt, Louis University of California, San Francisco
The genetics of restricted, repetitive behavior: An inbred mouse model Lewis, Mark University of Florida
The genetic control of social behavior in the mouse Blanchard, Robert University of Hawai'i at Manoa
A comparative developmental connectivity study of face processing Joseph, Jane University of Kentucky
A mouse knock-in model for ENGRAILED 2 autism susceptibility Millonig, James University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Serotonin, corpus callosum, and autism Lin, Rick University of Mississippi Medical Center
Characterization of a novel mouse model of restricted repetitive behaviors Moy, Sheryl University of North Carolina at Chapel Hill
Neuropharmacology of motivation and reinforcement in mouse models of autistic spectrum disorders Malanga, C.J. University of North Carolina School of Medicine
Functional genomic dissection of language-related disorders Fisher, Simon University of Oxford
Neurobiology of sociability in a mouse model system relevant to autism Brodkin, Edward University of Pennsylvania
Neurobiology of sociability in a mouse model system relevant to autism (supplement) Brodkin, Edward University of Pennsylvania
Behavioral and physiological consequences of disrupted Met signaling Levitt, Pat University of Southern California
Novel genetic animal models of autism Powell, Craig University of Texas Southwestern Medical Center
Animal models of autism: Pathogenesis and treatment Powell, Craig University of Texas Southwestern Medical Center
Dysregulation of PI3K/AKT in social interaction deficits and autism spectrum disorders with macrocephaly Parada, Luis University of Texas Southwestern Medical Center
Mouse genetic model of a dysregulated serotonin transporter variant associated with autism Veenstra-Vanderweele, Jeremy Vanderbilt University
Transgenic mouse model to address heterogeneity in autism spectrum disorders Blakely, Randy Vanderbilt University
Using zebrafish and chemical screening to define function of autism genes Sive, Hazel Whitehead Institute for Biomedical Research
Caspr2 dysfunction in autism spectrum disorders Robbins, Elissa Yale University
Integrated approach to the neurobiology of autism spectrum disorders Vaccarino, Flora Yale University

Objective Cumulative Funding Table

IACC Strategic Plan Objective 2008 2009 2010 2011 2012 Total
Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.

IACC Recommended Budget: $75,000,000 over 5 years
4.5
$15,879,827
42 projects

4.S.B
$20,162,709
70 projects

4.S.B
$23,229,501
92 projects

4.S.B
$21,606,118
89 projects

4.S.B
$21,232,514
94 projects

$102,110,669
4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.

Progress: More than 90 projects were supported to develop animal models.

Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built. The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.